Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

Mach, François; Catapano, Alberico L.; Koskinas, Konstantinos C.; Casula, Manuela; Badimon, Lina; Chapman, M. John; Backer, Guy De; Ference, Brian А.; Graham, Ian; Halliday, Alison; Mihaylova, Borislava; Pedersen, Terje R.; Riccardi, Gabriele; Sabatine, Marc S.; Taskinen, Marja‐Riitta; Tokgözoğlu, Lâle; Wiklund, Olov; Nibouche, Djamaleddine; Zelveian, Parounak; Siostrzonek, Peter; Najafov, Ruslan; Borne, Philippe van de; Pojskić, Belma; Postadzhiyan, Arman; Kypris, Lambros; Špinar, Jindřich; Larsen, Mogens Lytken; Eldin, Hesham Salah; Viigimaa, Margus; Strandberg, Timo; Ferrières, Jean; Agladze, Rusudan; Laufs, Ulrich; Rallidis, Lοukianos S.; Bajnok, László; Gudjonsson, Thorarinn; Maher, Vincent; Henkin, Yaakov; Gulizia, Michele Massimo; Bajraktari, Gani; Kerimkulova, Alina; Latkovskis, Gustavs; Hamoui, Omar; Šlapikas, Rimvydas; Visser, Laurent; Dingli, Philip; Ivanov, Victoria; Bošković, Aneta; Nazzi, M.; Visseren, Frank L.J.; Mitevska, Irena; Retterstøl, Kjetil; Jankowski, Piotr; Fontes‐Carvalho, Ricardo; Gaiță, Dan; Ezhov, M.; Foscoli, Marina; Pella, Daniel; Fras, Zlatko; Isla, Leopoldo Pérez de; Hagström, Emil; Lehmann, Roger; Abid, Leïla; Özdoğan, Öner; Mitchenko, O.; Patel, Riyaz; Windecker, Stephan; Aboyans, Victor; Baigent, Colin; Collet, Jean‐Philippe; Dean, Veronica; Delgado, Victoria; Fitzsimons, Donna; Gale, Chris P; Grobbee, Diederick E.; Halvorsen, Sigrun; Hindricks, Gerhard; Iung, Bernard; Jüni, Peter; Katus, Hugo A.; Landmesser, Ulf; Leclercq, Christophe; Lettino, Maddalena; Lewis, Basil S.; Merkely, Béla; Müeller, Christian; Petersen, Steffen E.; Petronio, Anna Sonia; Richter, Dimitrios J; Roffi, Marco; Shlyakhto, Evgeny; Simpson, Iain; Sousa-Uva, Miguel; Touyz, Rhian M.

doi:10.1016/j.atherosclerosis.2019.12.004

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As per the American School of Cardiology/American Heart Affiliation (ACC/AHA) and Canadian Cardiovascular Society (CCS) rules, high-risk patients ought to have an objective LDL cholesterol centralization of >1.8mmol/L or a decrease in LDL cholesterol of - ----------------------------------------------------------------------------------------Received on 24-09-2022 Accepted on 17-02-2023 over half from the benchmark. There is debate over the relative benefits of employing LDL cholesterol upper limits alone, deciding how much LDL cholesterol reduction should be pursued, and defining particular therapy goals 2 .…”

Section: Introductionmentioning

confidence: 99%

Meta-Analysis of Lowering LDL Cholesterol and its Impact on the Cardiovascular System

Badalyan¹,

Markosyan²,

Tariq³

et al. 2023

PJMHS

View full text Add to dashboard Cite

Background: By lowering LDL cholesterol levels, the risk of coronary heart disease (CHD) and other serious vascular events can be significantly reduced. In order to prevent cardiovascular illnesses (CVD), mainly coronary heart disease, LDL-cholesterol (LDL-C) levels must be tightly controlled on both a primary and secondary level (CHD). Despite the fact that patients in primary prevention experience a higher absolute number of atherosclerotic cardiovascular (CV) events than those in secondary prevention of CVD, subjects in primary prevention frequently receive little attention when it comes to the clinical management of LDL-C levels. Aim: To summarise the research supporting LDL cholesterol reduction treatments for elderly people. Method: For this meta-analysis, we searched PubMed, GOOGLE SCHOLAR, SCI.HUB, MEDLINE, and Embase for publications released between January 1, 2017, and December 28, 2021. As recommended by the 2018 American Academy of Cardiology and American Heart Association guidelines, randomised controlled trials evaluating cardiovascular outcomes of an LDL cholesterol-lowering medicine with a median follow-up of at least 2 years and data on older patients (aged 75 years).The search for literature source was limited to randomized controlled trials (human being). This meta-analysis, comprised of 24 trials from the Cholesterol Therapy Trialists' Collaboration meta-analysis plus five other trials, used data from six journals. 21492 (8%) of the 244090 participants in 29 studies, were over the age of 75. Among them, 11750 (54%) came from statin trials, 6209 (28%) from ezetimibe trials, and 3533 (16%) from PCSK9 inhibitor trials. We conducted network meta-analyses for the statins and non statin treatments. Results: Of the 244090 participants in 29 studies, 21492(8%) were over 75. These included 3533 (16%) from PCSK9 inhibitor studies, 11750 (54%) from statin trials, and 6209 (28%) from ezetimibe trials. A median follow-up period of 2 to 6 years was used. Without statistically differentiating from the risk reduction in patients under the age of 75 (085 [078-092]; pinteraction=037), LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) by 26% for 1 mmol/L reduction in LDL cholesterol (RR 074 [95% CI 061-089]; p=00019).In older patients, there was no statistically significant difference in the RRs for statin (0.82 [0.73-0.91] and non-statin (0.67 [0.47-0.95]; pinteraction=0.64) treatment. Reduced LDL cholesterol in older persons was shown to benefit all components of the composite, including coronary revascularization (080 [066-096], stroke (073 [061-087], and myocardial infarction (080 [071-090]. Practical implication: This meta analysis can be used to improve the treatment of people withlowering LDL cholesterol. Conclusion: The viability and security of diminishing LDL cholesterol in more seasoned adults are now supported by further research provided by this meta-analysis. By non-statin and statin LDL cholesterol-bringing down medication, we identified a risk reduction for major vascular events that were at least as effective as that observed in younger patients Keywords: LDL, Meta-analysis, Cardiovascular, Cholesterol,Atherosclerosis, Primary and secondary prevention.

show abstract

Section: Introductionmentioning

confidence: 99%

Meta-Analysis of Lowering LDL Cholesterol and its Impact on the Cardiovascular System

Badalyan¹,

Markosyan²,

Tariq³

et al. 2023

PJMHS

View full text Add to dashboard Cite

show abstract

“…The recommendation of PS supplementation to treat hypercholesterolemia is 2 g/day. 13 Some authors have shown that amounts from 0.8 g/day were effective in reducing cholesterol. 14 It is not possible to reach the recommended PS intake only with the consumption of vegetable foods, as their habitual diet contains 150‒400 mg/day.…”

Section: Introductionmentioning

confidence: 99%

Plasma lathosterol measures rates of cholesterol synthesis and efficiency of dietary phytosterols in reducing the plasma cholesterol concentration

Nunes

Ilha

Ferreira

et al. 2022

Clinics

View full text Add to dashboard Cite

The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study

Jun

Kang

Hwang

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

Cited by 10 publications

References 0 publications

Meta-Analysis of Lowering LDL Cholesterol and its Impact on the Cardiovascular System

Meta-Analysis of Lowering LDL Cholesterol and its Impact on the Cardiovascular System

Plasma lathosterol measures rates of cholesterol synthesis and efficiency of dietary phytosterols in reducing the plasma cholesterol concentration

The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study

Contact Info

Product

Resources

About